Shares of Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) have been assigned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, thirteen have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $64.50.
Several analysts have recently issued reports on RAPP shares. JonesTrading increased their price target on shares of Rapport Therapeutics from $50.00 to $82.00 and gave the stock a “buy” rating in a research report on Wednesday, October 21st. TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a report on Tuesday, October 20th. HC Wainwright reissued a “buy” rating and issued a $66.00 price target on shares of Rapport Therapeutics in a research report on Tuesday, October 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapport Therapeutics in a research note on Thursday, October 15th. Finally, Wells Fargo & Company cut their price objective on Rapport Therapeutics from $50.00 to $47.00 and set an “overweight” rating on the stock in a research report on Thursday, November 5th.
Read Our Latest Stock Analysis on RAPP
Rapport Therapeutics Trading Up 1.2%
Rapport Therapeutics stock traded up $0.30 during midday trading on Friday, reaching $26.15. 315,634 shares of the stock traded hands, compared to its average volume of 1,639,416. The company has a 50-day simple moving average of $31.93 and a two-hundred day simple moving average of $35.51. Rapport Therapeutics has a 12-month low of $22.06 and a 12-month high of $52.93. The firm has a market cap of $1.55 billion, a PE ratio of -8.25 and a beta of 1.40.
Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last released its earnings results on Wednesday, November 4th. The company reported ($0.84) earnings per share for the quarter, beating the consensus estimate of ($1.20) by $0.36. Equities research analysts anticipate that Rapport Therapeutics will post -3.34 earnings per share for the current year.
Insider Transactions at Rapport Therapeutics
In related news, Director John Maraganore purchased 9,411 shares of the business’s stock in a transaction on Thursday, October 22nd. The shares were bought at an average price of $26.45 per share, for a total transaction of $248,920.95. Following the acquisition, the director directly owned 9,411 shares in the company, valued at $248,920.95. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Cheryl Gault sold 10,000 shares of the company’s stock in a transaction dated Wednesday, September 30th. The stock was sold at an average price of $33.19, for a total value of $331,900.00. Following the sale, the chief operating officer owned 139,914 shares in the company, valued at approximately $4,643,745.66. This trade represents a 6.67% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last 90 days, insiders bought 1,031,174 shares of company stock valued at $22,023,898 and sold 46,477 shares valued at $1,958,709. 12.48% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Rapport Therapeutics
A number of institutional investors and hedge funds have recently made changes to their positions in RAPP. Algert Global LLC acquired a new position in Rapport Therapeutics during the 2nd quarter worth approximately $9,327,000. Johnson & Johnson purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $74,360,823. Legal & General Group Plc acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at $940,000. Bank of America Corp DE acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at $3,170,000. Finally, Walleye Capital LLC acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at $4,257,000.
About Rapport Therapeutics
Rapport Therapeutics is a Boston-based biotechnology company developing medicines for neurological and psychiatric disorders. Founded in 2022, the company focuses on small molecules designed to act on mechanisms that regulate the movement and function of proteins in the brain. Its research platform is intended to identify targets involved in neuronal signaling, including interactions that influence ion channels. Rapport’s pipeline includes RAP-219, an investigational medicine that modulates AMPA receptors and is being developed for focal epilepsy.
See Also
- Five stocks we like better than Rapport Therapeutics
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Rapport Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rapport Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
